The U.S. Food and Drug Administration Approves Zanubrutinib for Waldenstrӧm Macroglobulinemia

On August 31, 2021, the U.S. Food and Drug Administration (FDA) announced it has approved zanubrutinib (BRUKINSA, BeiGene), for adult patients with Waldenstrӧm macroglobulinemia (WM).

The drug had previously been approved for the treatment of mantle cell lymphoma (MCL) in adults patients who have received at least one prior therapy.

“Each lymphoma patient’s experience is unique, and the approval of zanubrutinib offers patients with Waldenstrӧm macroglobulinemia a new treatment option and new opportunity for hope,” said Meghan Gutierrez, Chief Executive Officer at the Lymphoma Research Foundation. “Chemotherapy-free agents and new methods of administration are important to ensuring that patients and their physicians, through shared decision making, are able to access the right treatments at the right time.”

For more information on the FDA approval of zanubrutinib (BRUKINSA), visit the FDA’s website.  To learn more about treatment options WM, visit the Waldenstrӧm Macroglobulinemia Learning Center.